Navigating TKI Selection in Leukemia Care

Quinto Gesiotto, MD, discusses optimal dosing strategies for ponatinib in the treatment of chronic-phase chronic myeloid leukemia.

Quinto Gesiotto, MD, discusses optimal ponatinib dosing strategies and evolving TKI sequencing considerations in chronic myeloid leukemia.

Dr Vale discusses data from a phase 2 trial evaluating blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Colin Vale, MD, discusses long-term efficacy data for blinatumomab and ponatinib in Ph+ B-ALL and significance of achieving remission without procedures.

Nicholas James Short, MD, discusses the roles of molecular and genetic testing in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Only 13% of US patients with CP-CML received FDA-recommended ponatinib dosing, highlighting gaps in dose optimization and the need for education.

Frontline dasatinib was linked to frequent T315I mutations at relapse in Ph+ ALL, while ponatinib showed fewer resistance mutations and favorable outcomes.